|
Oct 2
|
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Oct 1
|
CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
|
|
Sep 30
|
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
|
|
Sep 30
|
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
|
|
Sep 25
|
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
|
|
Sep 24
|
Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia
|
|
Jul 25
|
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
|
|
Mar 30
|
10 Best Long Term ASX Stocks To Invest In
|
|
Mar 19
|
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
|
|
Feb 25
|
An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 21% Undervalued
|
|
Feb 23
|
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
|
|
Jan 31
|
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
|
|
Jan 16
|
Harris Poll Survey Finds People Receiving Treatment for CIDP Are Interested in Exploring More Convenient Treatment Options
|
|
Jan 10
|
Why Does China Remain Terrible at Soccer? Xi Jinping Has One Answer
|
|
Dec 21
|
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
|
|
Dec 21
|
CSL Seqirus Commends the National Advisory Committee on Immunization for Preferential Recommendation of Enhanced Influenza Vaccines for Adults 65 and Older
|
|
Dec 14
|
CSL's Garadacimab, a First-in-Class Factor XIIa Inhibitor, Receives FDA and EMA Filing Acceptance
|
|
Dec 12
|
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B
|
|
Nov 28
|
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the first Self-Amplifying mRNA vaccine approved for COVID in adults
|
|
Sep 5
|
Arcturus Therapeutics and CSL Announce European Medicines Agency Validates Marketing Authorization Application for ARCT-154 Vaccine to Prevent COVID-19
|